The Role of B7-H4 in Tumor Vaccine

NCT06156150 · tracked via the Priya Life Science China tracker

Sponsor

Huashan Hospital

Phase

Observational

Started

2023-11-26

Last updated

2023-12-05

Condition(s) studied

Glioma

Investigational drug(s) / intervention(s)

tumor vaccine →

tumor vaccine: DC vaccine produced by the Team

Study summary

Glioma patients have poor prognosis because of limited choices of treatment. Therapeutic cancer vaccines have been proved to improve survival in glioma, but resistance is a new challenge for vaccine treatment, and the mechanism is unclear. The applicant found in previous papers that glioma cells induced B7-H4 overexpression in macrophages, and the expression level of B7-H4 is highly correlated with vaccine resistance. Preliminary experiments indicated that B7-H4 protein in macrophages inhibited the expression of ATF3, STAT1 and CXCL9/10, which also resulted in decreased T cell infiltration in glioma model of mouse and was a negative factor of vaccine benefits. Therefore, the applicant hypothesize that B7-H4 inhibits STAT1 transcription by reducing expression of ATF3, resulting in decreased phosphorylated-STAT1 in nucleus, which inhibiting expression and secretion of chemokines 9/10. Thereby, reduced infiltration of T cells in microenvironment will be followed, which ultimately promotes resistance of vaccine treatment in glioma. The follow-up plan of this project will be conducted based on the cells, organoid platform and animal experiments to confirm the role and mechanism of macrophage-derived B7-H4 in secretion of chemokines for T cells and treatment resistance of vaccines. Moreover, the DC vaccine produced by team of the applicant will be used to assess the probability of reversing vaccine resistance when intervening B7-H4 axis. Finally, a model for evaluating clinical benefits from vaccine will be established based on data from clinical trials combining with expression of B7-H4 and clinicopathologic features. This study will provide new evidences for the treatment of cancer vaccines in gliomas.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: Inclusion Criteria: The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological results of frozen section during operation were gliomas; 3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis; 4. Sign informed consent. Exclusion Criteria: Patients who meet any of the following criteria will not be included in this study: 1. Participants in other clinical trials; 2. Pregnant women.

Primary outcome measure(s)

IHC analysis — 36 months
Different expression level of proteins (CD3,CD8,B7-H4 et.ac) in Gliomas with different grades and molecular subgroups (100 cases) will be measured using immunohistochemical.

Trial sites (1)

Facility	City	Region	Status
Di Chen	Shanghai	Shanghai Municipality	Recruiting

More Huashan Hospital trials in China

Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients Recruiting

Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome Recruiting

The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function Recruiting

Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China Recruiting

Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens Recruiting

Other trials for the same condition

3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery Active, not recruiting

Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma Starting soon

Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial Recruiting

Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence Recruiting

Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06156150 on ClinicalTrials.gov ↗ ← All trials in China